Antibody, Dermatology, Drugs and Genomics - Clinical Research Informer

Sanofi wagers $400m on miRecule muscular dystrophy therapy

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA

RNA Genetics Dermatology Antibody

This week in drug discovery (12-16 December)

Drug Discovery World

DECEMBER 16, 2022

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. . First AML patient successfully transplanted with investigational drug . The post This week in drug discovery (12-16 December) appeared first on Drug Discovery World (DDW).

Drugs

Drugs Vaccination Vaccine Genetics

Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody

Antibody Vaccination Vaccine Dermatology

Listen now: Last episode of DDW Highlights for 2022

Drug Discovery World

DECEMBER 19, 2022

You can listen below, or find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. . The post Listen now: Last episode of DDW Highlights for 2022 appeared first on Drug Discovery World (DDW).

Genetics

Genetics Drugs Development Dermatology

The next generation of AI

Drug Discovery World

APRIL 15, 2024

The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications. AI is undoubtedly one of the key technologies that is set to impact drug discovery and development practices. AI is undoubtedly one of the key technologies that is set to impact drug discovery and development practices.

Antibody

Antibody Drugs In-Vivo Life Science

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

The drug appears to inhibit IL-6, IL-1beta, TNF-alpha and other pro-inflammatory cytokines and chemokines. All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. The trial will investigate 105 patients for the drug, which is made up of autologous CD34+ cells.

Trials

Trials Allergies In-Vitro Antibody

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

JULY 23, 2021

Food and Drug Administration (FDA), Bristol Myers Squibb has made the difficult decision to voluntarily withdraw the indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who were previously treated with sorafenib from the U.S. endocrinopathies and dermatologic reactions) are discussed below.

Hormones

Hormones Trials Genome Genomics

First Anti-PD-1 in Combination With Chemotherapy Approved for the First-Line Treatment of Esophageal and GEJ Carcinoma, Regardless of Histology or PD-L1 Expression

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. KENILWORTH, N.J.–(BUSINESS

HR

HR FDA Approval Containment Genome

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

The Pharma Data

MARCH 11, 2021

Food and Drug Administration (FDA) will hold a public meeting of the Oncologic Drugs Advisory Committee (ODAC) between April 27-29, 2021 to discuss accelerated approvals in oncology impacted as part of the Agency’s industry-wide review. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Trials

Trials Hormones Genome Genomics

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. KENILWORTH, N.J.–(BUSINESS Head and Neck Squamous Cell Cancer.

FDA Approval

FDA Approval Containment Trials Genome

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions. Embryo-Fetal Toxicity.

Trials

Trials Hormones Clinical Trials Clinical Trials

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions. Embryo-Fetal Toxicity.

Trials

Trials Hormones Clinical Trials Clinical Trials

Clinical Research Informer

Sanofi wagers $400m on miRecule muscular dystrophy therapy

This week in drug discovery (12-16 December)

Trending Sources

Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry

Listen now: Last episode of DDW Highlights for 2022

The next generation of AI

Clinical Catch-Up: January 18-22 | BioSpace

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

First Anti-PD-1 in Combination With Chemotherapy Approved for the First-Line Treatment of Esophageal and GEJ Carcinoma, Regardless of Histology or PD-L1 Expression

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

Stay Connected